菲律宾母乳喂养婴儿的免疫健康生物标志物和粪便微生物群
菲律宾母乳喂养婴儿的免疫健康生物标志物和粪便微生物群:一项前瞻性观察性研究
This will be a prospective observational study aiming to investigate immune health biomarkers and fecal microbiota in 48-60 Filipino breastfed infants from birth to 12 months of age. An optional follow-up period of approximately 2 years will follow.
研究概览
详细说明
This will be a prospective observational study in healthy term infants who are exclusively breastfed. Approximately 48-60 healthy breastfed infants aged ≥14 to ≤35 days at enrollment will be recruited and followed up until 12 month of age at 6 on-site visits: V1 (baseline), V3 (2 months), V5 (4 months), V6 (6 month), V7 (10months) and V8 (12 months).
The 12-month observational period will be followed by a 2year optional follow-up period for a total duration of the study of approximately 3 years.
The primary objective of this clinical study is to characterize early immune system development in breastfed Filipino infants by investigating infant blood markers of systemic immunity.
The secondary objectives will include the characterization of infant fecal markers of immune health and gut barrier function, infant blood and fecal microbiome, interactions between immune development and microbiome maturation, infant fecal metabolic profile and fecal pH, infant gastrointestinal (GI) tolerance, infant anthropometric measurements, infant complementary food intake as well as infant illness and infection.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Manila
-
Manila、Manila、菲律宾、1780
- Asian Hospital and Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Approximately 60 healthy breastfed infants aged ≥14 to ≤35 days at enrollment. To ensure balanced sex representation of the study population, approximately 30 males and 30 females will be enrolled in the study.
描述
Inclusion Criteria:
-
Written informed consent is obtained from parent(s)/ legally authorized representative(s) (LAR(s)).
-
Parent(s)/ LAR(s) must be able to provide evidence of parental authority and identity.
-
Parents/ LARs must understand the informed consent and other study documents.
-
Infants whose parent(s)/ LAR (s) has consented to blood collection as per protocol.
-
Able to temporarily store stool samples in a household freezer.
-
Infants whose parent(s)/LAR(s) are willing and able to comply with scheduled visits, and the requirements of the study protocol.
-
Infants whose parent(s)/LAR(s) can be contacted directly by telephone throughout the study.
-
Infants must meet all the following inclusion criteria to be eligible for enrollment into the study:
- Healthy term infant (≥37 weeks of gestation)
- At enrollment visit, postnatal age ≥14 to ≤35 days (date of birth = day 0)
- Birth weight is appropriate for gestational age (i.e., ≥ 2500g and ≤ 4500g)
- Infant has exclusively received breastmilk from birth to enrollment, and parent intends to continue exclusive breastmilk feeding until infant age 6 months.
Exclusion Criteria:
-
A medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:
- Evidence of major congenital malformations (e.g., cleft palate, extremity malformation).
- Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis).
- Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgment of the investigator, would make the infant inappropriate for entry into the study. Of note, children who are normally healthy but at the time of enrolment suffering from acute illness in a minor condition which are common in childhood and do not require some of the exclusionary medication mentioned below can be enrolled.
-
Presently receiving or have received prior to enrolment any of the following: medication(s) or supplement(s) which are known or suspected to affect the following: fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes); stool microbiota and characteristics (e.g., oral, or systemic antibiotics, glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose); growth (e.g., insulin or growth hormone); gastric acid secretion.
-
Infants whose parent(s) has(ve) not reached legal age of majority (18 years old) upon enrollment.
-
Currently participating or having participated in any interventional clinical trials since birth.
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Markers of systemic immunity
大体时间:Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months and 12months
|
Descriptive statistics of plasma immune proteomics using mass cytometry or immunoassays, and vaccine-specific antibodies assessed by ELISA |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months and 12months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fecal markers of immune health and gut barrier
大体时间:Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
|
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
|
Infant fecal microbiome
大体时间:Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12months
|
Microbiota composition, diversity, community types, and abundance of bacteria taxa |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12months
|
|
Fecal metabolic profile and pH
大体时间:Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
pH and fecal organic acids, such as lactate, propionate, butyrate, acetate, valerate and total fecal organic acids, in wet stool weight and per dry stool weight |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
|
Plasma Metabolomics
大体时间:Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, and 12 months
|
Untargeted Plasma metabolomics Analyses |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, and 12 months
|
|
GI Tolerance
大体时间:Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Weight
大体时间:Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
Measurement of weight in grams |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Length
大体时间:Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
Measurement of length in cm |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Head circumference
大体时间:Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
Measurement of head circumference in cm |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Z-scores and percentiles
大体时间:Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months.
|
Changes in weight-for-age, weight-for-length, length-for-age, BMI-for-age, and head-circumference-for-age z-scores and percentiles calculated according to WHO standards |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months.
|
|
Infant illness and infection
大体时间:Infant age 6 months
|
Descriptive data and overall score derived from the Pediatric Immune System Index Questionnaire completed by parents |
Infant age 6 months
|
|
Infant Complementary Food Intake
大体时间:Infant age 6-12months
|
Descriptive data from complementary food questionnaire and 3-day food record |
Infant age 6-12months
|
|
Long-term infant illness (during the optional follow-up)
大体时间:Infant age 12 months, 18 months, 24 months, 30 months, and 36 months
|
Descriptive data from the Infant Illness Questionnaire completed by parents |
Infant age 12 months, 18 months, 24 months, 30 months, and 36 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Adverse Events
大体时间:From infant age ≥14 to ≤35 days to 12 months
|
Incidents of adverse events from time of ICF signing at baseline, age ≥14 to ≤35 days, through the last study visit at age 12 months |
From infant age ≥14 to ≤35 days to 12 months
|
|
Concomitant medications and treatments
大体时间:From infant age ≥14 to ≤35 days to 12 months
|
All concomitant medications / treatments (including type and duration) used to treat illnesses and other conditions will be recorded continuously from time of ICF signing at baseline, age ≥14 to ≤35 days, through the last study visit at age 12 months |
From infant age ≥14 to ≤35 days to 12 months
|
合作者和调查者
调查人员
- 首席研究员:Maria Rosario JK Capeding, MD、Asian Hospital and Medical Center, Philippines
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.